Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and opticept trials

Background. Three randomized-controlled trials have examined the utility of mycophenolic acid (MPA) therapeutic drug monitoring in kidney transplant recipients. Each used a different methodology to estimate MPA exposure (pre-dose concentrations [C(0)], multiple regression-derived limited sampling strategies [LSSs], and Bayesian estimation in Opticept, FDCC [fixed dose versus concentration controlled] and APOMYGERE [adaption de Posologie du MMF en Greffe Renale] trials, respectively). Results were conflicting. This study aimed to compare the ability of these methodologies to predict AUC(0-12) in an independent cohort of kidney transplant recipients